You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Drug used to treat lymphoma outperforms remdesivir against Covid: Study

According to the scientists, the findings suggest that pralatrexate could potentially be repurposed to treat COVID-19

cancer drugs | Coronavirus

Press Trust of India  |  Beijing 

A health worker in personal protective equipment (PPE) collects a swab sample from a man at the Sadar Bazar market to conduct tests for the coronavirus disease (COVID-19), in Delhi on Wednesday.

A chemotherapy medication originally developed to treat cancer could potentially be repurposed to inhibit the replication of the novel and treat COVID-19, according to a study based on computer simulations and lab experiments.

The research, published in the journal PLOS Computational Biology, combined multiple computational techniques that simulate drug-virus interactions from different, complimentary perspectives.

Using this hybrid approach, scientists from the Shenzhen Institutes of Advanced Technology in China, screened 1,906 existing drugs for their potential ability to inhibit replication of the by targeting a viral protein called RNA-dependent RNA polymerase (RdRP).

The researchers identified four promising drugs, which were then tested against the SARS-CoV-2 virus in lab experiments.

They said two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus, and further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir -- a drug that is currently used to treat some COVID-19 patients.

According to the scientists, the findings suggest that pralatrexate could potentially be repurposed to treat COVID-19.

However, the researchers said the chemotherapy drug may prompt significant side effects and is used for people with terminal lymphoma, so they added that immediate use for COVID-19 patients is not guaranteed.

But the research highlighted the importance of the new screening strategy to identify drugs that could be repurposed.

"We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," said study author Haiping Zhang of the Shenzhen Institutes of Advanced Technology.

The researchers are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, January 03 2021. 16:18 IST